Last Updated:
Searching
Create account to add to watchlist!
Create account to add to watchlist!

Cactus Acquisition Corp. 1 Ltd - CCTS

  • Commons

    $9.96

    +0.00%

    CCTS Vol: 0.0

  • Warrants

    $0.12

    +0.00%

    CCTSW Vol: 0.0

  • Units

    $9.99

    +0.00%

    CCTSU Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 125.7M
Average Volume: 31.0K
52W Range: $9.81 - $10.76
Weekly %: +0.00%
Monthly %: +0.20%
Inst Owners: 0

Info

Target: Searching
Days Since IPO: 246
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-third of one warrant
Trust Size: 10000000.0M

Management

Our directors, director nominees and executive officers are as follows: Ofer Gonen serves as our Chief Executive Officer and is also a member of the board of directors. He has been the Chief Executive Officer of CBI since February 2017, with more than 20 years of experience in managing life sciences investments and business collaborations in both the United States and Israel. Prior to 2017, he served as a Vice President at CBI from September 2003 until February 2017. Mr. Gonen serves as a board member of several portfolio companies of CBI, including Gamida Cell (Nasdaq: GMDA) and MediWound (Nasdaq: MDWD), and as a managing partner at Anatomy Medical Fund. Mr. Gonen holds a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction. Mr. Gonen’s extensive knowledge and experience in the healthcare sphere, including as a director of CBI’s public portfolio companies, make him qualified to serve on our board of directors, given our search for a business combination in our target industries. Stephen T. Wills serves as our Chief Financial Officer. He also serves as the Chief Financial Officer (since 1997), and Chief Operating Officer (since 2011), of Palatin Technologies. Mr. Wills serves as a board member of Gamida Cell (Nasdaq: GMDA), MediWound (Nasdaq: MDWD) and Amryt Pharma (Nasdaq: AMYT). Mr. Wills has over 20 years of life sciences/healthcare experience, and his qualifications include his extensive operational, accounting/auditing, financing, fund-raising, acquisition, business development, licensing, divestiture, and healthcare experience, in addition to his strong technological background and significant experience with bankers, analysts and investors in the biopharmaceutical industry. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University. Nachum Shamir serves as our Chairman of the Board. Mr. Shamir serves as Chairman, President, and Chief Executive Officer of Luminex Corporation (Nasdaq: LMNX), which develops, manufactures, and markets a variety of proprietary biological testing technologies, and, which he joined in October, 2014. Mr. Shamir previously served, from 2006 to 2014, as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract. Prior to joining Given Imaging, Mr. Shamir was Corporate Vice President of Eastman Kodak Company and President of Eastman Kodak´s Transaction and Industrial Solutions Group. Additionally, he served over 10 years at Scitex Corporation in positions of increasing responsibility, including President and CEO from 2003 to 2004. Prior to 2003, Mr. Shamir held senior management positions at various international companies, mainly in the Asia Pacific regions. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University. Mr. Shamir is qualified to serve on the board of directors because his significant experience in managing biotechnology companies, both as a board member and as an executive, will help to guide our board in our search for strong target biotechnology companies. Hadar Ron, M.D. serves as a member of our board of directors. Since 2000, Dr. Ron has been a founder and managing partner of Israel Healthcare Ventures (IHCV), a fund focused on investing in global and Israeli companies in the fields of medical devices, biotechnology, pharmaceutical and medical-related IT. Dr. Ron is a physician and attorney by education. Her background includes extensive medical, legal and private equity management experience. Dr. Ron is closely familiar with the field of development and commercialization of medical products and systems, medical IT and data, and has wide experience serving as a board member of global public and private companies, including, among others: Inmode Medical Ltd. (NASDAQ: INMD), GIView Ltd. and Together Pharma Ltd. (TASE: TGTR). She earned an M.D. and LLB, each from the Tel Aviv University. Dr. Ron is qualified to serve on the board of directors because she will assist in our board’s search for, and assessment of, Israel-related target companies, and their technology, within the fields of medical devices, biotechnology, pharmaceuticals and medical-related IT. 109 Table of Contents David J. Shulkin, M.D. serves as a member of our board of directors. Since 2018, Dr. Shulkin has served as the President of Shulkin Solutions, LLC, which works with healthcare organizations and companies to foster innovation and improve well-being for patients. Previously, Dr. Shulkin served as the ninth United States Secretary of Veterans Affairs from February 2017 to March 2018 and the Under Secretary of Veterans Affairs for Health from July 2015 to February 2017. Prior to coming to such appointments, Dr. Shulkin was a healthcare executive, having served as chief executive of leading hospitals and health systems including Beth Israel Medical Center in New York City and Morristown Medical Center in Northern New Jersey. Dr. Shulkin has also held numerous physician leadership roles including the Chief Medical Officer of the University of Pennsylvania Health System, the Hospital of the University of Pennsylvania, Temple University Hospital, and the Medical College of Pennsylvania Hospital. Dr. Shulkin has held academic positions including the Chairman of Medicine and Vice Dean at Drexel University School of Medicine. As an entrepreneur, Dr. Shulkin founded and served as the Chairman and CEO of DoctorQuality one of the first consumer-orientated sources of information for quality and safety in healthcare. He has served on boards of managed care companies, technology companies, and health care organizations. Dr. Shulkin was the 2018 University of Pennsylvania Leonard Davis Institute Distinguished Health Policy Fellow. He is board-certified internist. He received his medical degree from the Medical College of Pennsylvania, his internship at Yale University School of Medicine, and a residency and Fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center. He received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania. Dr. Shulkin is qualified to serve on the board of directors due to his significant management experience in the healthcare and technology industries. David Sidransky, M.D. serves as a member of our board of directors. Since July 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is a co-founder and Managing Partner of Israel Biotech Fund. Dr. Sidransky currently serves on the board of directors of several public and private companies, including Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Champions Oncology (NASDAQ: CSBR), Orgenesis (NASDAQ: ORGS), and is the chairman of the board of directors of Ayala Pharmaceuticals (NASDAQ: AYLA). Dr. Sidransky served as Director of the American Association for Cancer Research (AACR) from 2005 to 2008. Dr. Sidransky received a B.S. in Chemistry from Brandeis University and an M.D. from Baylor College of Medicine. Dr. Sidransky is qualified to serve on the board of directors because his extensive knowledge and experience in the biotechnology and biopharmaceutical spheres, both in medical practice and through the lens of public company management, make him ideally suited to assist in our search for a business combination in our target industries. Number, Terms of Office and Appointment of Officers and Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of five members. Holders of our founders shares will appoint each of our directors prior to consummation of this offering for a two-year term, and holders of our public shares will not have the right to vote on the appointment of directors during such term. The provisions of our amended and restated memorandum and articles of association regarding director term may only be amended by a special resolution passed by the holders of at least 90% of our shares as, being entitled to do so, vote in a general meeting. Subject to any other special rights applicable to the shareholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the directors present and voting at the meeting of our board or by a majority of the holders of our founders shares. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association will provide that our officers may consist of a Chairman, Chief Executive Officer, President, Chief Financial Officer, Vice Presidents, Secretary, Assistant Secretaries, Treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors 110 Table of Contents has determined that each of Drs. Hadar Ron, David Shulkin and David Sidransky, and Mr. Nachum Shamir, is an “independent director” as defined in the Nasdaq listing standards and applicable SEC rules. Our audit committee and compensation committee will each be entirely composed of independent directors meeting Nasdaq’s and the SEC’s additional requirements applicable to members of those committees. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Officer and Director Compensation None of our officers or directors has received any cash compensation for services rendered to us. Each of our independent directors will invest, prior to the closing of this offering, as a limited partner holding a minority, non-controlling interest in our sponsor and will therefore hold an indirect interest in the founders shares held by our sponsor. In addition, our sponsor, officers and directors, and any of their respective affiliates, will be reimbursed for any bona-fide, documented out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. In addition, we may pay a customary financial consulting fee to an affiliate of our sponsor, which will not be made from the proceeds of this offering held in the trust account prior to the completion of our initial business combination. We may pay such financial consulting fee in the event such party or parties provide us with specific target company, industry, financial or market expertise, as well as insights, relationships, services or resources that we believe are necessary in order to assess, negotiate and consummate an initial business combination. The amount of any such financial consulting fee we pay will be based upon the prevailing market for similar services for comparable transactions at such time and will be subject to the review of our audit committee pursuant to the audit committee’s policies and procedures relating to transactions that may present conflicts of interest. Our audit committee will also review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting, management or other fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our shareholders in connection with a proposed business combination. It is unlikely the amount of such compensation will be known at the time such materials are distributed, because the directors of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined by a compensation committee constituted solely by independent directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after the initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Pursuant to Nasdaq listing rules we will establish three standing committees — an audit committee in compliance with Section 3(a)(58)(A) of the Exchange Act, a compensation committee and, if required in the future, a nominating committee, each comprised of independent directors. Under Nasdaq listing rule 5615(b)(1), a company listing in connection with its initial public offering is permitted to phase in its compliance with the independent committee requirements. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Drs. Hadar Ron and David Shulkin, and Mr. Nachum Shamir, will serve as members of our audit committee and Mr. Shamir will serve as the chairman of the audit committee. Under the Nasdaq listing standards and applicable SEC rules, we are required to have at least three members of the 111 Table of Contents audit committee, all of whom must be independent, subject to certain phase-in provisions. Each such prospective member of our audit committee meets the independent director standard under Nasdaq listing standards and under Rule 10A-3(b)(1) of the Exchange Act. Each member of the audit committee is or will be financially literate and our board of directors has determined that Dr. Ron qualifies as an “audit committee financial expert” as defined in applicable SEC rules and has accounting or related financial management expertise. We will adopt an audit committee charter, which will detail the purpose and principal functions of the audit committee, including: • the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us; • pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; • reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence; • setting clear hiring policies for employees or former employees of the independent auditors; • setting clear policies for audit partner rotation in compliance with applicable laws and regulations; • obtaining and reviewing a report, at least annually, from the independent auditors describing (i) the independent auditor’s internal quality-control procedures and (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within, the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; • meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; • reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and • reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. Compensation Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of directors. Dr. Ron and Mr. Shamir will serve as members of our compensation committee and Dr. Ron will serve as the chairperson of the compensation committee. Under the Nasdaq listing standards and applicable SEC rules, we are required to have at least two members of the compensation committee, all of whom must be independent, subject to certain phase-in provisions. Each such person meets the independent director standard under Nasdaq listing standards and Rule 10C-1 of the Exchange Act applicable to members of the compensation committee. We will adopt a compensation committee charter, which will detail the purpose and responsibility of the compensation committee, including: • reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation (if any is paid by us), evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; 112 Table of Contents • reviewing and making recommendations to our board of directors with respect to the compensation and any incentive-compensation of all of our other officers; • reviewing our executive compensation policies and plans; • implementing and administering our incentive compensation equity-based remuneration plans; • assisting management in complying with our proxy statement and annual report disclosure requirements; • approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; • producing a report on executive compensation to be included in our annual proxy state

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q QUARTERLY REPORT 2022-05-16 https://www.sec.gov/Archives/edgar/data/1865861/000121390022027175/f10q0322_cactusacq1.htm
10-K ANNUAL REPORT 2022-03-31 https://www.sec.gov/Archives/edgar/data/1865861/000121390022016735/f10k2021_cactusacq1.htm
SC 13G SCHEDULE 13G 2022-03-21 https://www.sec.gov/Archives/edgar/data/1865861/000121390022013707/ea157089-13gcactus_cactus1.htm
3 2022-03-18 https://www.sec.gov/Archives/edgar/data/1865861/000121390022013420/xslF345X02/ownership.xml
SC 13G SC 13G 2022-02-08 https://www.sec.gov/Archives/edgar/data/1865861/000110465922013410/tm225488d9_sc13g.htm
SC 13G/A CACTUS ACQUISITION CORP. 1 LIMITED 2022-02-03 https://www.sec.gov/Archives/edgar/data/1865861/000090266422001016/p22-0558sc13ga.htm
SC 13G FORM SC 13G 2022-01-13 https://www.sec.gov/Archives/edgar/data/1865861/000106299322001023/formsc13g.htm
8-K CURRENT REPORT 2021-12-28 https://www.sec.gov/Archives/edgar/data/1865861/000121390021067740/ea153116-8k_cactusacq1.htm
10-Q QUARTERLY REPORT 2021-12-16 https://www.sec.gov/Archives/edgar/data/1865861/000121390021065630/f10q0921_cactusacq1.htm
SC 13G CACTUS ACQUISITION CORP. 1 LIMITED 2021-11-12 https://www.sec.gov/Archives/edgar/data/1865861/000090266421004893/p21-2487sc13g.htm
SC 13G 2021-11-09 https://www.sec.gov/Archives/edgar/data/1865861/000093583621000612/cactusacquisition13g.htm
8-K CURRENT REPORT 2021-11-08 https://www.sec.gov/Archives/edgar/data/1865861/000121390021057329/ea150095-8k_cactusacq1.htm
3 2021-11-04 https://www.sec.gov/Archives/edgar/data/1865861/000121390021056676/xslF345X02/ownership.xml
8-K CURRENT REPORT 2021-11-03 https://www.sec.gov/Archives/edgar/data/1865861/000121390021056499/ea149899-8k_cactusacq1.htm
3 2021-11-03 https://www.sec.gov/Archives/edgar/data/1865861/000121390021056403/xslF345X02/ownership.xml
3 2021-11-03 https://www.sec.gov/Archives/edgar/data/1865861/000121390021056398/xslF345X02/ownership.xml
3 2021-11-03 https://www.sec.gov/Archives/edgar/data/1865861/000121390021056396/xslF345X02/ownership.xml
3 2021-11-03 https://www.sec.gov/Archives/edgar/data/1865861/000121390021056394/xslF345X02/ownership.xml
424B4 PROSPECTUS 2021-11-01 https://www.sec.gov/Archives/edgar/data/1865861/000121390021055853/f424b41121_cactusacq.htm
EFFECT 2021-10-28 https://www.sec.gov/Archives/edgar/data/1865861/999999999521004072/xslEFFECTX01/primary_doc.xml
S-1MEF REGISTRATION STATEMENT 2021-10-28 https://www.sec.gov/Archives/edgar/data/1865861/000121390021055144/ea149546-s1mef_cactusacq1.htm
CERT 2021-10-28 https://www.sec.gov/Archives/edgar/data/1865861/000135445721001241/8A_Cert_CCTS.pdf
8-A12B FOR REGISTRATION OF CERTAIN CLASSES 2021-10-28 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054959/ea149459-8a12b_cactusacq1.htm
CORRESP 2021-10-27 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054821/filename1.htm
CORRESP 2021-10-27 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054819/filename1.htm
CORRESP 2021-10-27 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054751/filename1.htm
CORRESP 2021-10-27 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054749/filename1.htm
CORRESP 2021-10-26 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054710/filename1.htm
CORRESP 2021-10-26 https://www.sec.gov/Archives/edgar/data/1865861/000121390021054708/filename1.htm
S-1/A REGISTRATION STATEMENT 2021-10-07 https://www.sec.gov/Archives/edgar/data/1865861/000121390021051829/fs12021a1_cactusacquisition1.htm
CORRESP 2021-07-20 https://www.sec.gov/Archives/edgar/data/1865861/000121390021037698/filename1.htm
S-1 REGISTRATION STATEMENT 2021-07-20 https://www.sec.gov/Archives/edgar/data/1865861/000121390021037688/fs12021_cactusacquisition1.htm
UPLOAD 2021-07-09 https://www.sec.gov/Archives/edgar/data/1865861/000000000021008479/filename1.pdf
DRS 2021-06-15 https://www.sec.gov/Archives/edgar/data/1865861/000121390021032544/filename1.htm